Issue Date: October 22, 2012
… And Heart Drug With Theravance
Merck & Co. and Theravance have formed a partnership to discover, develop, and commercialize small molecules directed at targets being investigated for their involvement in hypertension and heart failure. Merck will make an up-front payment of $5 million, gaining an exclusive license to Theravance’s therapeutic candidates. Theravance is eligible to receive additional milestone payments of up to $148 million for the first indication, as well as royalties.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society